

Details of Revenue

(Billions of yen)

	2017.3	2018.3	2019.3	2020.3	2021.3	2022.3 (Forecast)
Revenue of Major Products						
OPDIVO Intravenous Infusion	103.9	90.1	90.6	87.3	98.8	110.0
FORXIGA Tablets	7.8	11.1	14.5	18.1	22.4	35.0
GLACTIV Tablets	29.4	27.4	26.9	26.1	25.5	24.5
ORENCIA for Subcutaneous Injection	11.6	14.1	17.4	19.8	21.9	22.5
PARSABIV Intravenous Injection	0.2	3.4	5.7	7.1	8.1	8.0
KYPROLIS for Intravenous Infusion	2.0	5.5	4.9	6.0	7.1	7.5
ONOACT for Intravenous Infusion	5.7	5.6	4.6	4.9	4.7	4.0
OPALMON Tablets	17.0	14.4	10.4	8.3	5.5	4.0
VELEXBRU Tablets	—	—	—	—	2.1	5.0
RIVASTACH Patches	8.9	8.9	8.9	8.5	6.6	3.0
BRAFTOVI Capsules	—	—	—	*	1.1	3.0
MEKTOVI Tablets	—	—	—	*	1.0	2.5
ONON Capsules	6.8	5.5	4.4	3.5	2.9	2.5
ONGENTYS Tablets	—	—	—	—	0.3	2.5
New products to be launched	—	—	—	—	—	2.5
(Note) Based on ex-manufacturer prices						
*Not disclosed.						
Breakdown of Revenue						
Revenue of goods and products	214.3	205.9	208.9	205.6	214.5	240.0
Royalty and others	30.5	55.9	79.7	86.8	94.7	105.0
OPDIVO Intravenous Infusion	26.7	39.8	58.5	61.6	59.8	
Keytruda® (Merck)	—	*	12.8	19.3	24.3	
Other	*	*	8.4	5.9	10.6	
*Not disclosed.						
Revenue by Region						
Japan	214.0	204.0	207.4	202.9	212.9	
Americas	27.3	52.5	72.3	81.5	85.6	
Asia	3.1	5.1	7.4	7.5	7.4	
Europe	0.4	0.2	1.6	0.5	3.4	